Combination therapeutics in complex diseases

Bing He; Cheng Lu; Guang Zheng; Xiaojuan He; Maolin Wang; Gao Chen; Ge Zhang; Aiping Lyu

doi:10.1111/jcmm.12930

Combination therapeutics in complex diseases

Bing He
, Cheng Lu
, Guang Zheng
, Xiaojuan He
, Maolin Wang
, Gao Chen
, Ge Zhang^*
, Aiping Lyu

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

97 Citations (Scopus)

54 Downloads (Pure)

Abstract

The biological redundancies in molecular networks of complex diseases limit the efficacy of many single drug therapies. Combination therapeutics, as a common therapeutic method, involve pharmacological intervention using several drugs that interact with multiple targets in the molecular networks of diseases and may achieve better efficacy and/or less toxicity than monotherapy in practice. The development of combination therapeutics is complicated by several critical issues, including identifying multiple targets, targeting strategies and the drug combination. This review summarizes the current achievements in combination therapeutics, with a particular emphasis on the efforts to develop combination therapeutics for complex diseases.

Original language	English
Pages (from-to)	2231-2240
Number of pages	10
Journal	Journal of Cellular and Molecular Medicine
Volume	20
Issue number	12
DOIs	https://doi.org/10.1111/jcmm.12930
Publication status	Published - 1 Dec 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

User-Defined Keywords

combination therapeutics
complex diseases
molecular network

Access to Document

10.1111/jcmm.12930

Full TextFinal published version, 336 KB

Cite this

@article{f403c42c4ee341508ec9c1a03bd42607,

title = "Combination therapeutics in complex diseases",

abstract = "The biological redundancies in molecular networks of complex diseases limit the efficacy of many single drug therapies. Combination therapeutics, as a common therapeutic method, involve pharmacological intervention using several drugs that interact with multiple targets in the molecular networks of diseases and may achieve better efficacy and/or less toxicity than monotherapy in practice. The development of combination therapeutics is complicated by several critical issues, including identifying multiple targets, targeting strategies and the drug combination. This review summarizes the current achievements in combination therapeutics, with a particular emphasis on the efforts to develop combination therapeutics for complex diseases.",

keywords = "combination therapeutics, complex diseases, molecular network",

author = "Bing He and Cheng Lu and Guang Zheng and Xiaojuan He and Maolin Wang and Gao Chen and Ge Zhang and Aiping Lyu",

note = "Funding Information: This work is supported by the Interdisciplinary Research Matching Scheme (IRMS) of Hong Kong Baptist University (RC-IRMS/12-13/02), the Research Committee of Hong Kong Baptist University (33-12-903), the Hong Kong Baptist University Strategic Development Fund (SDF13-1209-P01), the National Science and Technology Major Projects for ?major New Drugs Innovation and Development? (2013ZX09301307) and the Hospital Authority (HA 820/126/19/19/14/6/12/1).",

year = "2016",

month = dec,

day = "1",

doi = "10.1111/jcmm.12930",

language = "English",

volume = "20",

pages = "2231--2240",

journal = "Journal of Cellular and Molecular Medicine",

issn = "1582-1838",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "12",

}

TY - JOUR

T1 - Combination therapeutics in complex diseases

AU - He, Bing

AU - Lu, Cheng

AU - Zheng, Guang

AU - He, Xiaojuan

AU - Wang, Maolin

AU - Chen, Gao

AU - Zhang, Ge

AU - Lyu, Aiping

N1 - Funding Information: This work is supported by the Interdisciplinary Research Matching Scheme (IRMS) of Hong Kong Baptist University (RC-IRMS/12-13/02), the Research Committee of Hong Kong Baptist University (33-12-903), the Hong Kong Baptist University Strategic Development Fund (SDF13-1209-P01), the National Science and Technology Major Projects for ?major New Drugs Innovation and Development? (2013ZX09301307) and the Hospital Authority (HA 820/126/19/19/14/6/12/1).

PY - 2016/12/1

Y1 - 2016/12/1

N2 - The biological redundancies in molecular networks of complex diseases limit the efficacy of many single drug therapies. Combination therapeutics, as a common therapeutic method, involve pharmacological intervention using several drugs that interact with multiple targets in the molecular networks of diseases and may achieve better efficacy and/or less toxicity than monotherapy in practice. The development of combination therapeutics is complicated by several critical issues, including identifying multiple targets, targeting strategies and the drug combination. This review summarizes the current achievements in combination therapeutics, with a particular emphasis on the efforts to develop combination therapeutics for complex diseases.

AB - The biological redundancies in molecular networks of complex diseases limit the efficacy of many single drug therapies. Combination therapeutics, as a common therapeutic method, involve pharmacological intervention using several drugs that interact with multiple targets in the molecular networks of diseases and may achieve better efficacy and/or less toxicity than monotherapy in practice. The development of combination therapeutics is complicated by several critical issues, including identifying multiple targets, targeting strategies and the drug combination. This review summarizes the current achievements in combination therapeutics, with a particular emphasis on the efforts to develop combination therapeutics for complex diseases.

KW - combination therapeutics

KW - complex diseases

KW - molecular network

UR - https://www.scopus.com/pages/publications/84987936742

U2 - 10.1111/jcmm.12930

DO - 10.1111/jcmm.12930

M3 - Review article

C2 - 27605177

AN - SCOPUS:84987936742

SN - 1582-1838

VL - 20

SP - 2231

EP - 2240

JO - Journal of Cellular and Molecular Medicine

JF - Journal of Cellular and Molecular Medicine

IS - 12

ER -

Combination therapeutics in complex diseases

Abstract

UN SDGs

User-Defined Keywords

Access to Document

Other files and links

Fingerprint

Cite this